David C Henshall Selected Research

Kainic Acid (Kainate)

1/2022	Microvascular stabilization via blood-brain barrier regulation prevents seizure activity.
1/2022	Increased expression of the ATP-gated P2X7 receptor reduces responsiveness to anti-convulsants during status epilepticus in mice.
11/2021	Antagomir-mediated suppression of microRNA-134 reduces kainic acid-induced seizures in immature mice.
10/2021	Detection of spontaneous seizures in EEGs in multiple experimental mouse models of epilepsy.
1/2021	Elevated blood purine levels as a biomarker of seizures and epilepsy.
12/2020	High concordance between hippocampal transcriptome of the mouse intra-amygdala kainic acid model and human temporal lobe epilepsy.
1/2020	Genetic deletion of microRNA-22 blunts the inflammatory transcriptional response to status epilepticus and exacerbates epilepsy in mice.
1/2020	P2X7 Receptor-Dependent microRNA Expression Profile in the Brain Following Status Epilepticus in Mice.
1/2019	Altered Biogenesis and MicroRNA Content of Hippocampal Exosomes Following Experimental Status Epilepticus.
1/2019	Context-Specific Switch from Anti- to Pro-epileptogenic Function of the P2Y1 Receptor in Experimental Epilepsy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David C Henshall Research Topics

Disease

81	Seizures (Absence Seizure) 01/2022 - 07/2002
66	Epilepsy (Aura) 08/2022 - 07/2002
52	Status Epilepticus (Complex Partial Status Epilepticus) 01/2022 - 02/2008
25	Temporal Lobe Epilepsy 01/2021 - 04/2004
14	Brain Injuries (Brain Injury) 10/2020 - 09/2002
13	Inflammation (Inflammations) 01/2022 - 01/2011
8	Neuroinflammatory Diseases 01/2022 - 01/2013
7	Gliosis 01/2020 - 06/2008
6	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 01/2004
5	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 01/2004
5	Ischemia 06/2011 - 09/2002
4	Schizophrenia (Dementia Praecox) 01/2022 - 01/2011
4	Brain Diseases (Brain Disorder) 01/2021 - 01/2017
4	Hypoxia (Hypoxemia) 01/2019 - 11/2015
4	Nervous System Diseases (Neurological Disorders) 01/2018 - 07/2012
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2015 - 01/2003
3	Pathologic Processes 01/2020 - 01/2016
3	Drug Resistant Epilepsy 12/2019 - 09/2012
3	Hippocampal Sclerosis 03/2015 - 01/2012
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022 - 05/2011
2	Neoplasms (Cancer) 01/2021 - 12/2007
2	Cognitive Dysfunction 11/2019 - 10/2019
2	Metabolic Bone Diseases (Osteopenia) 01/2018 - 10/2016
2	Hypophosphatasia 01/2018 - 10/2016
2	AIDS-Related Complex (ARC) 01/2017 - 05/2011
2	Infarction (Infarctions) 01/2015 - 11/2004
2	Brain Ischemia (Cerebral Ischemia) 02/2009 - 01/2003

Drug/Important Bio-Agent (IBA)

41	Kainic Acid (Kainate)IBA 01/2022 - 07/2002
40	MicroRNAs (MicroRNA)IBA 01/2022 - 11/2011
38	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2003
24	Biomarkers (Surrogate Marker)IBA 08/2022 - 04/2014
15	Purinergic P2X7 ReceptorsIBA 01/2022 - 01/2012
13	Adenosine Triphosphate (ATP)IBA 01/2022 - 09/2013
12	Pharmaceutical PreparationsIBA 01/2022 - 01/2009
12	AntagomirsIBA 11/2021 - 07/2012
9	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022 - 01/2012
7	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2017
7	OligonucleotidesIBA 01/2021 - 09/2013
6	Antisense OligonucleotidesIBA 11/2021 - 04/2004
5	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021 - 11/2013
5	Protein Isoforms (Isoforms)IBA 01/2018 - 10/2006
5	Transcription Factors (Transcription Factor)IBA 12/2016 - 04/2004
5	CaspasesIBA 03/2009 - 05/2002
4	Pilocarpine (Ocusert)FDA LinkGeneric 10/2021 - 07/2015
4	CytokinesIBA 01/2021 - 01/2011
4	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2003
4	locked nucleic acidIBA 01/2018 - 09/2013
4	Type I Tumor Necrosis Factor ReceptorsIBA 01/2011 - 05/2003
4	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2011 - 09/2003
3	Lorazepam (Ativan)FDA LinkGeneric 01/2022 - 04/2004
3	ConvulsantsIBA 01/2022 - 06/2008
3	Pentylenetetrazole (Metrazol)IBA 01/2021 - 03/2017
3	Ion Channels (Ion Channel)IBA 01/2021 - 01/2015
3	Phenobarbital (Luminal)FDA Link 01/2018 - 11/2015
3	EnzymesIBA 01/2018 - 01/2003
3	3- (5- (2,3- dichlorophenyl)- 1H- tetrazol- 1- yl)methylpyridineIBA 01/2017 - 09/2013
3	Oxygen (Dioxygen)IBA 11/2015 - 02/2005
3	BenzodiazepinesIBA 10/2015 - 04/2012
3	CalciumIBA 08/2015 - 04/2004
3	14-3-3 Proteins (14-3-3 Protein)IBA 01/2012 - 06/2008
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2011 - 09/2003
3	Death Domain ReceptorsIBA 02/2008 - 04/2004
3	Death-Associated Protein KinasesIBA 04/2004 - 09/2003
3	Caspase 8 (Caspase-8)IBA 04/2004 - 09/2003
2	LipopolysaccharidesIBA 01/2022 - 11/2004
2	Midazolam (Versed)FDA LinkGeneric 01/2022 - 10/2015
2	Blood Proteins (Serum Proteins)IBA 01/2021 - 02/2013
2	Messenger RNA (mRNA)IBA 01/2020 - 01/2016
2	ElementsIBA 01/2020 - 02/2005
2	Transfer RNA (tRNA)IBA 01/2020 - 01/2019
2	Carrier Proteins (Binding Protein)IBA 01/2020 - 01/2012
2	ChromatinIBA 10/2018 - 02/2005
2	Vitamin B 6IBA 01/2018 - 10/2016
2	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 01/2018 - 10/2016
2	Alkaline PhosphataseIBA 01/2018 - 10/2016
2	Untranslated RNA (Noncoding RNA)IBA 01/2018 - 03/2015
2	Proteasome Endopeptidase Complex (Proteasome)IBA 07/2017 - 01/2017
2	salicylhydroxamic acid (SHAM)IBA 07/2017 - 12/2008
2	CholesterolIBA 03/2017 - 10/2012
2	Purinergic P2X4 ReceptorsIBA 01/2016 - 11/2013
2	Purinergic Receptors (Receptors, Purine)IBA 01/2016 - 08/2015
2	CationsIBA 01/2016 - 06/2014
2	Caspase 3 (Caspase-3)IBA 11/2015 - 04/2006
2	Molecular Chaperones (Chaperone, Molecular)IBA 06/2015 - 05/2003
2	Glucose (Dextrose)FDA LinkGeneric 01/2015 - 02/2005
2	LigandsIBA 11/2013 - 01/2012
2	Immunoglobulin G (IgG)IBA 02/2013 - 09/2012
2	Bcl-2-Like Protein 11IBA 06/2011 - 04/2004
2	Dopamine (Intropin)FDA LinkGeneric 05/2011 - 06/2008
2	Neuropeptide YIBA 01/2010 - 06/2008
2	Calmodulin (Calcium-Dependent Activator Protein)IBA 04/2004 - 09/2003
2	Diazepam (Valium)FDA LinkGeneric 04/2004 - 09/2002
1	2,2'-Dipyridyl (2,2 Bipyridine)IBA 08/2022
1	MetalsIBA 08/2022
1	phenazine FDA Link 08/2022
1	PhenanthrolinesIBA 08/2022

Therapy/Procedure

13	Therapeutics 01/2022 - 01/2004
4	Drug Therapy (Chemotherapy) 01/2022 - 10/2015
2	Intraperitoneal Injections 01/2021 - 06/2014
2	Injections 03/2017 - 01/2016